All Online

1 - 12 of 18 results

Refine

Active filters

Cardiovascular Outcomes Trials
1 CME CREDIT

Adults with type 2 diabetes mellitus (T2DM) have a two- to four-fold increase in risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/26/2020, and they are subject to change as new information is published.


0.58 CME CREDIT

During this session (part 3 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for SGLT2 inhibitors and use a patient case to discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


0.75 CME CREDIT

During this session (part 2 of 3 from webcast series), Dr. Aguilar and Dr. Thethi review data from cardiovascular outcomes trials for GLP-1 RAs and DPP-4 inhibitors. Using 2 patient cases, they discuss the American Diabetes Association guidelines for individualizing diabetes therapy for patients with ASCVD, heart failure, and chronic kidney disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


0.25 CME CREDIT

During this session (part 1 of 3 webcast videos), Dr. Tina Thethi reviews the association between type 2 diabetes and cardiovascular disease as well as provides an overview of the American Diabetes Association guidelines designed to help individualize therapy for patients with T2DM and concurrent heart failure and/or atherosclerotic cardiovascular disease. *Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/3/2019, and they are subject to change as new information is published.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


1 CME CREDIT

Over ten percent of the U.S. population suffers disproportionate cardiometabolic risk because of their type 2 diabetes (T2DM). In light of recent data, GLP-1 receptor agonists (GLP-1 RAs) have taken on a more prominent role in T2DM management algorithms. This session will discuss how you can distinguish among GLP-1 RAs and use them in your practice to help manage the risks that these patients face beyond glucose control. A member of the Diabetes Sisters organization will also be joining us to discuss their experience with starting a GLP-1 RA as a patient.


Cardiovascular Risk in T2DM

1.50 CME/MOC
1.48 AANP | 1.13 Pharmacology


0.25 CME CREDIT

GLP-1 Receptor Agonists: A Cardiology Perspective (Podcast)

0.25 CME/MOC
0.25 AANP | 0.25 Pharmacology

In this podcast, cardiologist Ty Gluckman will take a deep dive into the cardiology benefits of glucagon like peptide-1 receptor agonists (GLP-1 RA). He will review the clinical trial data which has resulted in GLP-1 RA incorporation into guidelines, which address patients who have both diabetes and atherosclerotic cardiovascular disease. Dr. Gluckman will bring the perspective of a cardiologist into the discussion of these agents with emerging significance in cardiovascular risk reduction.


0.25 CME CREDIT

Listen to this podcast for a concise summary of the latest clinical practice guidelines for identifying glycemic targets and managing T2DM in various patient populations including, older adults, individuals with increased cardiac or renal risk, and those at risk for hypoglycemic events.


0.75 CME CREDIT

Two leading experts in type 2 diabetes management will review the benefits and limitations of GLP-1 receptor agonists, including a new oral agent in this class, by providing expert syntheses of clinical trial data and demonstrating how to turn this information into useful, actionable guidance for routine patient care.